Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 201 - 210 of 317

Selected Filters:
7 July 2022

Dapivirine Vaginal Ring for HIV Prevention: Modeling health outcomes, drug resistance and cost‐effectiveness

This paper evaluates the potential epidemiological impact and cost-effectiveness of dapivirine vaginal ring PrEP among 22- to 45-year-old women in KwaZulu-Natal, South Africa.

Financing & Costing, Research

External Link
7 July 2022

From Proof-of-Concept to Prevention Phenomenon in Five Years

This timeline, first appearing in AVAC Report 2014/15: HIV Prevention on the Line, shows PrEP going from proof-of-concept to prevention phenomenon in five years and can be used to anticipate and speed action on the next generation of ARV-based prevention options.

Research

External Link
7 July 2022

Kenya Dapivirine Ring Rollout Scenarios

As Kenya considers introduction of the dapivirine ring, a new HIV prevention method for women, an outstanding question is how and where the ring should be introduced relative to oral PrEP. To support decision making, the PROMISE Consortium developed this analysis to consider several possible scenarios, defined by HIV incidence among women and adolescent girls…

Research, Service Delivery

Document
7 July 2022

OPTIONS Knowledge, Attitude and Practice Literature Review and Survey Analysis

This literature review looks at completed and ongoing studies that include knowledge, attitude and practice (KAP) surveys in sub-Saharan Africa of providers and potential providers of oral preexposure prophylaxis (PrEP) to adolescent girls and young women (AGYW).

Research, Service Delivery

Document
7 July 2022

Health Care Workers’ Knowledge, Attitudes, and Practices Related to Oral PrEP Provision to Adolescent Girls and Young Women in Zimbabwe

This poster describes the results of a cross-sectional qualitative study, interviewing providers at public, private, and nongovernmental health facilities in Zimbabwe offering PrEP to explore providers’ attitudes toward and experiences delivering PrEP to AGYW.

Research, Service Delivery

Presentation
7 July 2022

Understanding Service Providers’ Knowledge of Oral PrEP and Attitudes Toward Provisionto Populations at Substantial HIV Risk in South Africa

This poster describes the results of a cross-sectional qualitative study, interviewing providers at public, private, and nongovernmental health facilities in South Africa offering PrEP to explore providers’ attitudes toward and experiences delivering PrEP to AGYW.

Research, Service Delivery

Document
7 July 2022

Microbicide Trials Network-043 – B-PROTECTED Study

Microbicide Trials Network-043, or B-PROTECTED, is a Phase IIIb open-label study that evaluated the safety and acceptability of the monthly dapivirine ring and daily oral PrEP in women who are breastfeeding, a time of heightened vulnerability for acquiring HIV.

Research

External Link
7 July 2022

Use of the Dapivirine vaginal ring and effect on cervical cytology abnormalities

This study aims to determine if the dapivirine vaginal ring and the ring device alone (flexible silicone matrix polymer) was associated with the development of cervical cytology abnormalities.

Research, Service Delivery

External Link
7 July 2022

Results from the HPTN 083 Trial

The HIV Prevention Trials Network (HPTN) held a community webinar to discuss the preliminary results of HPTN 083, a global randomized, controlled, double-blinded study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) (Truvada) for pre-exposure prophylaxis (PrEP) in transgender women and cisgender men who have sex…

Research

External Link
7 July 2022

Results from the HPTN 084 Trial

The HIV Prevention Trials Network (HPTN) hosted a community webinar to discuss the primary results of HPTN 084, a randomized, double-blind controlled trial designed to evaluate the efficacy and safety of long-acting injectable cabotegravir (CAB LA) to prevent the sexual acquisition of HIV in cisgender women in sub-Saharan Africa.

Research

External Link